Risperdal Lawsuit: En Banc Hearing Denied: Pa. Superior Court
Risperdal Lawsuit: En Banc Hearing Denied: Pa. Superior Court
Introduction
Defendants named in the Risperdal lawsuit, Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, had filed a motion early March requesting a rehearing before the entire Pennsylvania Superior Court for reconsideration of a related January 2018 ruling. On March 16, 2018, the Pennsylvania Superior Court turned down this request.
As per the January 2018 court decision, the court allowed the plaintiff involved in the lawsuit to pursue punitive damages; this decision came after a three-judge panel found that the trial court should have considered the law of plaintiffs’ home states when considering whether or not punitive damages should be allowed. Anticipating thousands of plaintiffs seeking similar awards, the defendants filed a motion to oppose the decision.
Comments
Latest News
SRI Gets FDA OK for High-Dose Naloxone Trial
Categories: Opioids
SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.
The approval was granted under an Investigational New Drug (IND)…
Spokane County to Get $5M in New Opioid Settlement
Categories: Opioids
Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.
The agreement addresses the company’s role in fueling…
Purdue, Sacklers Agree to New $7.4B Opioid Settlement
Categories: Opioids
All 50 U.S. states, along with the District of Columbia and U.S. territories, have agreed to a $7.4 billion settlement with Purdue Pharma, the manufacturer of OxyContin.
This deal addresses allegations that the company’s aggressive and…